Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.Matthew S. Davids, Andrew W. Roberts, Jianning Yang et al.|Journal of Clinical Oncology|2014Cited by 91
Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)Matthew S. Davids, Andrew W. Roberts, John M. Pagel et al.|Blood|2013Cited by 69
ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.John F. Seymour, Andrew W. Roberts, Matthew S. Davids et al.|Journal of Clinical Oncology|2014Cited by 56
The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) PatientsMatthew S. Davids, Andrew W. Roberts, John F. Seymour et al.|Blood|2013Cited by 53
Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib TherapyJeffrey A. Jones, John C. Byrd, Anthony R. Mato et al.|Blood|2015Cited by 36